26 results match your criteria adchf

  • Page 1 of 1

Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?

Card Fail Rev 2020 Mar 19;7:e02. Epub 2021 Feb 19.

Faculty of Medicine, Universitas Pelita Harapan Tangerang, Indonesia.

Heart failure is currently one of the leading causes of morbidity and mortality. Patients with heart failure often present with acute symptoms and may have a poor prognosis. Recent evidence shows differences in clinical characteristics and outcomes between de novo heart failure (DNHF) and acute decompensated chronic heart failure (ADCHF). Read More

View Article and Full-Text PDF

Hemodynamic Profiles of Cardiogenic Shock Depending on Their Etiology.

J Clin Med 2020 Oct 22;9(11). Epub 2020 Oct 22.

Cardiology Department, APHM, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Centre for CardioVascular and Nutrition Research (C2VN), Aix-Marseille Univ, INSERM 1263, INRA 1260, Hopital Nord, 13015 Marseille, France.

The pathophysiology of cardiogenic shock (CS) varies depending on its etiology, which may lead to different hemodynamic profiles (HP) and may help tailor therapy. We aimed to assess the HP of CS patients according to their etiologies of acute myocardial infarction (AMI) and acute decompensated chronic heart failure (ADCHF). We included patients admitted for CS secondary to ADCHF and AMI. Read More

View Article and Full-Text PDF
October 2020

Differences in clinical characteristics and outcome of de novo heart failure compared to acutely decompensated chronic heart failure - systematic review and meta-analysis.

Acta Cardiol 2020 Apr 7:1-11. Epub 2020 Apr 7.

Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.

Recent evidence showed that the characteristics and outcome of those with de novo heart failure (HF) and acutely decompensated chronic heart failure (ADCHF) were different. We aimed to perform a comprehensive search on the clinical characteristics and outcome of patients with de novo HF and ADCHF. We performed a comprehensive search on de novo/new onset acute HF vs ADCHF from inception up until December 2019. Read More

View Article and Full-Text PDF

Acutely decompensated versus acute heart failure: two different entities.

Heart Fail Rev 2020 11;25(6):907-916

Department of Cardiology, Larissa University General Hospital, P.O. Box 1425, 411 10, Larissa, Greece.

Heart failure (HF) has been classified in chronic HF (CHF) and acute HF (AHF). The latter has been subdivided in acutely decompensated chronic HF (ADCHF) defined as the deterioration of preexisting CHF and de novo AHF defined as the rapid development of new symptoms and signs of HF that requires urgent medical attention. However, ADCHF and de novo AHF have fundamental pathophysiological differences. Read More

View Article and Full-Text PDF
November 2020

[Characteristic of infectious status in patients with acutely decompencated chronic heart failure and its impact on annual prognosis].

Kardiologiia 2019 Sep 16;59(8S):56-62. Epub 2019 Sep 16.

Research Institute of Emergency medicine named after I. I. Janelidze.

Aim: The assessment of infectious status in patients with acutely decompensated chronic heart faiure (ADCHF) without evident signs of acute inflammatory stress and its impact on the 1 year prognosis.

Material And Methods: Totally, 65 patients with ADCHF of ischemic origin investigated, age 67,3±2,3 y.o. Read More

View Article and Full-Text PDF
September 2019

[Prognostic value of acute cardiorenal syndrome in patients with acute cardiac pathology].

Kardiologiia 2019 Sep 16;59(8S):44-55. Epub 2019 Sep 16.

Tyumen State Medical University.

Aim: To assess the prevalence and prognostic value of AKI in patients with acute decompensation of chronic heart failure (ADCHF) with a reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF) or acute coronary syndrome (ACS), to identify predictors of AKI.

Materials And Methods: In a prospective study included 863 patients, of which 141 with ADCHF, 446 - non-ST-elevation acute coronary syndromes (NSTE-ACS) and 276 - ST-segment elevation myocardial infarction (STEMI). AKI was diagnosed according to KDIGO recommendations. Read More

View Article and Full-Text PDF
September 2019

Differences in Mortality of New-Onset (De-Novo) Acute Heart Failure Versus Acute Decompensated Chronic Heart Failure.

Am J Cardiol 2019 08 25;124(4):554-559. Epub 2019 May 25.

Heart Research Follow-up Program, University of Rochester, Rochester, New York.

Minimal attention has been paid to understanding the implications of the chronicity of heart failure (HF) diagnosis on prognosis of hospitalized patients with acute HF (AHF). We aimed to assess the differences in outcomes between hospitalized patients with AHF that are new-onset (de-novo) AHF and acutely decompensated chronic HF (ADCHF). We analyzed data of 2,328 patients with AHF, who were enrolled in the HF survey in Israel. Read More

View Article and Full-Text PDF

Prognostic Effect of Guideline-Directed Therapy Is More Noticeable Early in the Course of Heart Failure.

J Korean Med Sci 2019 May 6;34(17):e133. Epub 2019 May 6.

Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.

Background: There have been few studies to evaluate the prognostic implications of guideline-directed therapy according to the temporal course of heart failure. This study assessed the relationship between adherence to guideline-directed therapy at discharge and 60-day clinical outcomes in acute heart failure (AHF) and acute decompensated chronic heart failure (ADCHF) separately.

Methods: Among 5,625 AHF patients who were recruited from a multicenter cohort registry of Korean Acute Heart Failure, 2,769 patients with reduced ejection fraction were analyzed. Read More

View Article and Full-Text PDF

Interactive and potentially independent roles of renin-angiotensin-aldosterone system blockade and the development of cardiorenal syndrome type 1 on in-hospital mortality among elderly patients admitted with acute decompensated congestive heart failure.

Int J Nephrol Renovasc Dis 2019 14;12:33-48. Epub 2019 Mar 14.

Department of Medicine, Section of Nephrology, University of Illinois at Chicago, Chicago, IL, USA.

Purpose: Cardiorenal syndrome type 1 (CRS1), defined as worsening renal function from acute decompensated congestive heart failure (ADCHF), is complicated by the fact that CRS1 limits the use of common therapeutic strategies, such as angiotensin converting-enzyme inhibitors (ACEIs) or angiotensin II-receptor blockers (A2RB). The present study examines retrospectively the role of ACEI/A2RB usage on in-hospital mortality among elderly ADCHF patients, in particular those who developed CRS1.

Methods: We retrospectively examined the effects of ACEI/A2RB usage and CRS1 development (in-hospital change in serum creatinine ≥0. Read More

View Article and Full-Text PDF

Hypoxia-inducible factor 1 (HIF-1) as a biomarker of acute kidney injury in patients with acute decompensation of chronic heart failure.

Kardiologiia 2019 Mar 7;59(2S):25-30. Epub 2019 Mar 7.

Federal State Budgetary Educational Institution, Ulyanovsk State University..

Actuality. Impaired kidney function adversely influences both immediate and remote prognosis for patients with chronic heart failure (CHF). However, early detection and prediction of acute kidney injury (AKI) are understudied. Read More

View Article and Full-Text PDF

Vascular phenotypes of acute decompensated vs. new-onset heart failure: treatment implications.

Authors:
Jorge Ferreira

ESC Heart Fail 2017 11 28;4(4):679-685. Epub 2017 Sep 28.

Department of Cardiology, Hospital Santa Cruz, CHLO, Av Prof Reynaldo Santos, 2790-134, Carnaxide, Portugal.

Aims: Acute heart failure (HF) is a frequent and life-threatening syndrome with heterogeneous clinical, haemodynamic, and neurohormonal features. This article describes the vascular phenotypes associated with acute decompensated chronic HF (ADCHF), and new-onset acute HF (NOAHF).

Data Synthesis: Worsening of chronic HF occurs with full activation of adaptive mechanisms that maintain blood pressure (BP) and systemic perfusion. Read More

View Article and Full-Text PDF
November 2017

Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry.

Clin Cardiol 2017 Oct 9;40(10):907-913. Epub 2017 Jun 9.

AMIS Plus, Zurich, Switzerland.

Background: Data on temporal trends of heart failure (HF) in acute coronary syndrome (ACS) are scarce.

Hypothesis: Improved treatment options may have led to lower case-fatality rates (CFRs) during the last years in ACS complicated by HF.

Methods: Patients of the nationwide Acute Myocardial Infarction in Switzerland (AMIS)-Plus ACS registry were analyzed from 2000 to 2014. Read More

View Article and Full-Text PDF
October 2017

[Value of N-terminal pro brain natriuretic peptide in predicting acute kidney injury in patients with acute decompensated chronic heart failure].

Ter Arkh 2017;89(3):78-84

Ulyanovsk State University, Ulyanovsk, Russia.

Aim: To investigate the prognostic value of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in the development of acute kidney injury (AKI) in patients with acute decompensated chronic heart failure (ADCHF).

Subjects And Methods: Eighty-three patients (55 (66%) men and 28 (34%) women; mean age, 65±11 years) with ADCHF were examined. AKI was diagnosed and classified according to the 2012 Kidney Disease Improving Global Outcomes Clinical Practice guidelines. Read More

View Article and Full-Text PDF

Ventricular conduction abnormalities as predictors of long-term survival in acute de novo and decompensated chronic heart failure.

ESC Heart Fail 2016 Mar 30;3(1):35-43. Epub 2015 Oct 30.

Heart and Lung Center, Cardiology Helsinki University Hospital Finland.

Aims: Data on the prognostic role of left and right bundle branch blocks (LBBB and RBBB), and nonspecific intraventricular conduction delay (IVCD; QRS ≥ 110 ms, no BBB) in acute heart failure (AHF) are controversial. Our aim was to investigate electrocardiographic predictors of long-term survival in patients with AHF and acutely decompensated chronic heart failure (ADCHF).

Methods And Results: We analysed the admission electrocardiogram of 982 patients from a multicenter European cohort of AHF with 3. Read More

View Article and Full-Text PDF

Demographics, Clinical Characteristics, Management, and Outcomes of Acute Heart Failure Patients: Observations from the Oman Acute Heart Failure Registry.

Oman Med J 2016 May;31(3):188-95

Department of Medicine, Al Nahdha Hospital, Muscat, Oman.

Objectives: We sought to describe the demographics, clinical characteristics, management and outcomes of patients in Oman with acute heart failure (AHF) as part of the Gulf aCute heArt failuRe rEgistry (CARE) project.

Methods: Data were analyzed from 988 consecutive patients admitted with AHF to 12 hospitals in Oman between 14 February and 14 November 2012.

Results: The mean age of our patients was 63±12 years. Read More

View Article and Full-Text PDF

Impact of anticoagulation on the effectiveness of loop diuretics in heart failure with cardiorenal syndrome and venous thromboembolism.

Blood Coagul Fibrinolysis 2014 Mar;25(2):180-2

aDepartament of Cardiology, City Hospital, Al. Niepodleglości 44, Olsztyn, Poland.

The limitations of diuretics in the treatment of acute decompensated heart failure (ADCHF) are progressive worsening of renal function and resistance to up-titrated doses. The occurrence of resistance to loop diuretics in patients with ADCHF is associated with worsening prognosis and increased mortality. In this study, we report two patients with ADCHF and resistance to loop diuretics suspected for venous thromboembolism, suggesting that heparin administered to ADCHF patients treated for venous thromboembolism with cardiorenal syndrome decreases right-ventricular overload and improves renal function. Read More

View Article and Full-Text PDF

Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.

Eur J Intern Med 2014 Jan 23;25(1):67-72. Epub 2013 Sep 23.

Centro Hospitalar do Porto, Portugal.

Background/objectives: Mineralocorticoid receptor antagonist (MRA) use in acutely decompensated chronic heart failure (ADCHF) may improve congestion through diuretic effect and prevent neurohormonal activation. We aimed to evaluate the clinical effect and safety of spironolactone in ADCHF.

Methods: Prospective, experimental, single-center, and single-blinded trial. Read More

View Article and Full-Text PDF
January 2014

Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors.

Clin Res Cardiol 2013 Oct 10;102(10):745-53. Epub 2013 Jul 10.

Centro Hospitalar do Porto, Porto, Portugal,

Background/objectives: Few data exist to help physicians in the use of diuretics to provide the greatest symptomatic benefit with the least adverse effect to patients and to select the subset of patients who require a more aggressive diuretic strategy and monitoring. The aim of this study is to identify early predictors of diuretic response in a selected group of patients with acutely decompensated chronic heart failure (ADCHF).

Methods: This was an observational, retrospective secondary analysis of a study including 100 patients with ADCHF. Read More

View Article and Full-Text PDF
October 2013

Long-term survival after hospitalization for acute heart failure--differences in prognosis of acutely decompensated chronic and new-onset acute heart failure.

Int J Cardiol 2013 Sep 13;168(1):458-62. Epub 2012 Oct 13.

Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.

Aims: To analyze the five-year mortality after hospitalization for acute heart failure (AHF) and compare predictors of prognosis in patients with and without a previous history of heart failure.

Methods: Patients with AHF (n=620) from the prospective multicenter FINN-AKVA study were classified as acutely decompensated chronic heart failure (ADCHF) or de-novo AHF if no previous history of heart failure was present. Both all-cause mortality during five years of follow-up and prognostic factors were determined. Read More

View Article and Full-Text PDF
September 2013

Brain natriuretic peptide in the evaluation of emergency department dyspnea: is there a role?

J Emerg Med 2012 Feb 26;42(2):197-205. Epub 2011 Nov 26.

Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

Background: Acute decompensated congestive heart failure (ADCHF) is a common etiology of dyspnea in emergency department (ED) patients. Delayed diagnosis of ADCHF increases morbidity and mortality. Two cardiac biomarkers, N-terminal-pro brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) have demonstrated excellent sensitivity in diagnostic accuracy studies, but the clinical impact on patient-oriented outcomes of these tests remains in question. Read More

View Article and Full-Text PDF
February 2012

Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure.

Int J Cardiol 2012 May 22;157(1):31-7. Epub 2010 Dec 22.

Second Department of Cardiology, Athens University Medical School, Attiko University Hospital, Athens, Greece.

Background: We investigated whether dobutamine-induced changes of the left atrial (LA) two-dimensional speckle tracking parameters are related to clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensate chronic heart failure (ADCHF).

Methods: Forty-six patients with ADCHF and LV ejection fraction <35%, were studied using dobutamine stress echocardiography before a 24-hour infusion of levosimendan. In a multivariable model, we included: dobutamine-induced LV contractile reserve, change (%) of LA volume, LV longitudinal strain rate and LA speckle tracking parameters to assess the improvement of NYHA class, 6-min walk distance and brain natriuretic peptide (BNP). Read More

View Article and Full-Text PDF

Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure.

Eur J Heart Fail 2010 Mar;12(3):239-48

Division of Emergency Care, Department of Medicine, Helsinki University Central Hospital, PO Box 340, Helsinki 00029 HUS, Finland.

Aims: Acute heart failure (AHF) has a poor prognosis. We evaluated 3- and 12-month mortality in different clinical classes of AHF patients from 30 European countries who were included in the EuroHeart Failure Survey (EHFS) II.

Methods And Results: Follow-up data were available for 2981 AHF patients, of these 62% had a history of chronic HF. Read More

View Article and Full-Text PDF

Newer treatments for decompensated heart failure: focus on levosimendan.

Authors:
Ferenc Follath

Drug Des Devel Ther 2009 Sep 21;3:73-8. Epub 2009 Sep 21.

Steering Group Drug Therapy, University Hospital Zürich, Raemistrasse 100, Zürich, Switzerland.

Acute heart failure (AHF) is a major cause of hospitalizations. Severe dyspnea, pulmonary congestion and low cardiac output with peripheral vasoconstriction and renal hypoperfusion is a main form of clinical presentation. Most patients with acute worsening have a pre-existing decompensated chronic heart failure (ADCHF), but AHF may also occur as a first manifestation of a previously unknown heart disease. Read More

View Article and Full-Text PDF
September 2009

Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.

Am J Cardiol 2008 Nov 4;102(9):1225-9. Epub 2008 Sep 4.

Heart Failure Unit and Second Cardiology Department, Attikon University Hospital, Athens, Greece.

Levosimendan reduces symptoms and improves hemodynamics in patients with acutely decompensated chronic heart failure (ADCHF). The aim of this study was to investigate (1) the association of changes induced by low-dose dobutamine stress echocardiography in 2-dimensional strain parameters with the corresponding changes in the left ventricular (LV) ejection fraction (EF) and LV outflow tract velocity time integral (VTI) in patients with ADCHF and (2) whether LV contractile reserve assessed by conventional and speckle-tracking echocardiography is associated with clinical and neurohumoral improvement after levosimendan treatment. Twenty-eight consecutive patients with ADCHF (mean age 65 +/- 10 years, mean New York Heart Association class 3. Read More

View Article and Full-Text PDF
November 2008

Nesiritide (Scios).

IDrugs 2002 Jul;5(7):703-9

Beth Israel Deaconess Medical Center, Non-invasive Cardiology Laboratory, Baker-3, 1 Deaconess Road, Boston, MA 02215, USA.

Nesiritide is a recombinant B-type (brain) natriuretic peptide developed by Scios for the potential treatment of congestive heart failure (CHF). In August 2001, the product was approved and launched in the US for the intravenous treatment of patients with acute decompensated congestive heart failure (ADCHF) who have dyspnea at rest or at minimal activity [418946], [420072]. By March 2002, Scios' European development partner, GlaxoSmithKline, expected to file a Marketing Authorization Application (MAA) for nesiritide in Europe in 2002 [446957]. Read More

View Article and Full-Text PDF
  • Page 1 of 1